Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer

Hui-Li Wong, Belinda Lee, Kathryn Field, Anna Lomax, Mark Tacey, Jeremy Shapiro, Joe McKendrick, Allan Zimet, Desmond Yip, Louise Nott, Ross Jennens, Gary Richardson, Jeanne Tie, Suzanne Kosmider, Phillip Parente, Lionel Lim, Prasad Cooray, Ben Tran, Jayesh Desai, Rachel WongPeter Gibbs

Research output: Contribution to journalArticleResearchpeer-review

31 Citations (Scopus)

Abstract

Background With an ever-increasing focus on personalized medicine, all factors known to affect treatment response need to be considered when defining optimal therapy for individual patients. While the prognostic impact of primary tumor site on colorectal cancer (CRC) outcomes is established, emerging data suggest potential differences in response to biologic therapies. We studied the impact of tumor site on bevacizumab efficacy in patients with metastatic CRC. Patients and Methods We analyzed data of patients in an Australian prospective multicenter metastatic CRC (mCRC) registry who received first-line chemotherapy. Tumor site was defined as right colon, cecum to transverse; left colon, splenic flexure to rectosigmoid; and rectum. Kaplan-Meier and Cox models were used for survival analyses. Results Of 926 patients, 297 had right colon, 354 left colon, and 275 rectum primary disease. Median age was 68.6, 65.9, and 63.3 years, respectively (P =.001). Right colon disease was significantly associated with intraperitoneal spread (P <.0001), while left colon and rectum disease preferentially metastasized to the liver and lungs, respectively (P <.0001 in both settings). A total of 636 patients (68.7%) received bevacizumab. Progression-free survival was superior for bevacizumab-treated patients in all groups but appeared greatest in right colon disease (hazard ratio, 0.46; 95% confidence interval, 0.36-0.60; P ≤.001). Overall survival was longest in patients with disease of the rectum, followed by left colon and right colon (median, 26.2, 23.6, and 18.2 months, respectively; P =.0004). Conclusion Tumor site appears to be prognostic in mCRC, with rectum and right colon disease associated with the best and worst outcomes, respectively. Patients who received bevacizumab in addition to chemotherapy had superior outcomes, with the effect appearing greatest in patients with right colon disease.

Original languageEnglish
Pages (from-to)9-15
Number of pages7
JournalClinical Colorectal Cancer
Volume15
Issue number2
DOIs
Publication statusPublished - Jun 2016

Keywords

  • Anti-VEGF therapy
  • Bowel cancer
  • Distal colorectal cancer
  • Personalized medicine
  • Proximal colorectal cancer

Cite this

Wong, H-L., Lee, B., Field, K., Lomax, A., Tacey, M., Shapiro, J., McKendrick, J., Zimet, A., Yip, D., Nott, L., Jennens, R., Richardson, G., Tie, J., Kosmider, S., Parente, P., Lim, L., Cooray, P., Tran, B., Desai, J., ... Gibbs, P. (2016). Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clinical Colorectal Cancer, 15(2), 9-15. https://doi.org/10.1016/j.clcc.2016.02.007